SCHEMBL22822792

SCHEMBL22822792

CNC(=O)c1cn(C)c2c(OC)cc(N(C)C)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CREBBP Q92793 2/20 0.41
▸ BRD4 O60885 1/20 0.41
▸ TP53 P04637 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.39
▸ ALDH1A1 P00352 5/20 0.39
▸ MEN1 O00255 4/20 0.39
▸ KMT2A Q03164 4/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ GLA P06280 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ NR4A2 P43354 1/20 0.39
▸ PLK1 P53350 1/20 0.39
▸ POLB P06746 2/20 0.39
▸ USP2 O75604 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19657307 0.83 ALDH1A1 (0.44) CREBBPBRD4KDM4EALDH1A1MEN1
SCHEMBL19657311 0.68 BRD4 (0.48) CREBBPBRD4KDM4EALDH1A1GLA
SCHEMBL5241461 0.68 NR4A2 (0.54) CREBBPBRD4KDM4EALDH1A1MEN1
SCHEMBL19657852 0.66 BRD4 (0.46) CREBBPBRD4KDM4EALDH1A1SMN1; SMN2
SCHEMBL19657743 0.66 BRD4 (0.46) CREBBPBRD4TP53KDM4EALDH1A1
SCHEMBL19657569 0.65 BRD4 (0.44) CREBBPBRD4TP53KDM4ESMN1; SMN2
SCHEMBL30993088 0.65 BRD4 (0.44) CREBBPBRD4KDM4EMEN1KMT2A
SCHEMBL22822275 0.65 BRD4 (0.44) CREBBPBRD4KDM4EALDH1A1GLA
SCHEMBL21024059 0.64 BRD4 (0.43) CREBBPBRD4KDM4EALDH1A1SMN1; SMN2
SCHEMBL19657300 0.64 BRD4 (0.43) CREBBPBRD4KDM4EALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11168070-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2021-11-09 — — US disclosed
US-20200399244-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2020-12-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399244-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC3 CREBBP 7/4885BRD4 12/4885TP53 2338/4885
US-11168070-B2 Therapeutic compounds and uses thereof EP300, HDAC1, HDAC11 CREBBP 6/4885BRD4 11/4885TP53 2245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback